Peer-reviewed veterinary case report
Sorafenib drug reduces bone cancer cells and causes cell death in dogs
By Wolfesberger, B et al.·Published in Research in veterinary science·2010·Department for Companion Animals and Horses·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
- Species:
- dog
Plain-English summary
A study found that sorafenib, a new cancer medication, can effectively reduce the number of osteosarcoma cells in dogs, which is a type of aggressive bone cancer. When tested on a specific canine osteosarcoma cell line, sorafenib significantly decreased cell survival and increased cell death after 72 hours of treatment. This suggests that sorafenib could be a promising option for treating bone cancer in dogs, especially since traditional chemotherapy often has limited success. While more research is needed, this finding offers hope for better treatment options for dogs with osteosarcoma.
People also search for: dog osteosarcoma treatment · sorafenib for canine cancer · bone cancer in dogs · chemotherapy for dog osteosarcoma
Abstract
Canine osteosarcoma, an aggressive cancer with early distant metastasis, shows still despite good chemotherapy protocols poor long term survival. The aim of our study was to determine whether sorafenib, a novel multikinase inhibitor, has any effect on D-17 canine osteosarcoma cells. A cell proliferation kit was used for detecting surviving cells after treatment for 72 h with sorafenib or carboplatin or their combination. A significant decrease of neoplastic cells was observed after incubation with 0.5-16 microM sorafenib or with 80-640 microM carboplatin. Using immunocytochemistry for activated caspase 3 to evaluate apoptosis, we found significantly more positive cells in the sorafenib treated groups. Paradoxically, expression of the nuclear proliferation marker Ki-67 was also significantly higher in sorafenib treated cells. The drug sorafenib showed potent antitumour activity against D-17 canine osteosarcoma cells in vitro, suggesting a potential as a therapeutic tool in the treatment of bone cancer in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19665156/